Inogen Inc
INGN Nasdaq· Orthopedic, Prosthetic & Surgical Appliances & Supplies
Last close · Oct 26, 2026
$7.08
KIRA · Stoqly’s AI analyst, in plain words
- Inogen Inc had $349M of revenue in fiscal 2025, up 3.9% on the year before. Over five years, revenue changed +2.5% a year on average.
- Its operating margin was −8.7%, up 4.0 pts: of every 100 in sales, about −9 is left after running the business.
- Inogen Inc lost $22.7M in fiscal 2025.
- Free cash flow was −$13.7M in fiscal 2025, −3.9% of revenue.
Market cap
$191M
P/E
—
Revenue
$349M
Net income
−$22.7M
Free cash flow
−$13.7M
Operating margin
−8.7%
Inogen Inc in 30 seconds · fiscal 2025
Are sales growing?
+3.9%
Only a little. Sales grew 3.9% last year.
Does it make a profit?
−6.5%
No. It lost money last year.
Does profit turn into cash?
−3.9%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Inogen Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 27, 2026
- Legal name
- Inogen Inc
- CIK
- 0001294133
Inogen Inc · INGN
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $358M | $377M | $316M | $336M | $349M |
| Revenue growth | 16.1% | 5.4% | −16.3% | 6.4% | 3.9% |
| Gross margin | 49.3% | 40.7% | 40.1% | 46.1% | 44.2% |
| Operating margin | 2.6% | −22.6% | −34.7% | −12.7% | −8.7% |
| Net income | −$6.3M | −$83.8M | −$102M | −$35.9M | −$22.7M |
| Net margin | −1.8% | −22.2% | −32.5% | −10.7% | −6.5% |
| Diluted EPS | −$0.28 | −$3.67 | −$4.42 | −$1.52 | −$0.86 |
| Cash | |||||
| Cash from operations | $23.6M | −$37.5M | −$3.2M | $5.9M | −$11.2M |
| Capital expenditure | $5.5M | $3.3M | $5.2M | $3.4M | $2.5M |
| Free cash flow | $18.2M | −$40.9M | −$8.5M | $2.6M | −$13.7M |
| FCF margin | 5.1% | −10.8% | −2.7% | 0.8% | −3.9% |
| Share count change | 2.3% | 1.6% | 1.4% | 2.1% | 12.5% |
| Debt and strength | |||||
| Cash and short-term investments | $246M | $187M | $128M | $114M | $120M |
| Shareholders' equity | $370M | $297M | $205M | $174M | $192M |
| Current ratio | 5.4x | 4.7x | 2.9x | 2.4x | 3.1x |
| Returns and quality | |||||
| Return on equity | −1.8% | −25.1% | −40.8% | −19.0% | −12.4% |
| Return on tangible equity | −2.3% | −31.7% | −64.0% | −26.8% | −15.1% |
| Piotroski F-score | 4 | 2 | 2 | 5 | 4 |
| Altman Z'' | 7.4 | 5.2 | 1.1 | 1.3 | 2.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.1M
1 insider
Of sales under plans
100%
$0.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Inogen Inc · INGN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $7.08 a share, the company is worth $191M.
Source: SEC EDGAR XBRL filings (CIK 0001294133). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.